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Hypermanganesemia with Dystonia, Polycythemia and Cirrhosis (HMDPC) due 
to mutation in the SLC30A10 gene. 
 
Abstract: 
Manganese (Mn) is an essential element for metabolic pathways but it can be toxic when present in 
excessive amounts in the body. Hypermanganesemia along with dystonia, polycythemia, characteristic 
MRI brain findings in the basal ganglia, and chronic liver disease are the hallmarks of an inherited Mn 
transporter defect due to mutations in the SLC30A10 gene. We are reporting three siblings who 
presented with features of dystonia, polycythemia, MRI brain showing basal ganglia hyperintensity on 
T1 weighted images and chronic liver disease. Blood Mn levels were markedly elevated in the affected 
patients. Mutation analysis of DNA samples of the affected children confirmed a homozygous missense 
mutation in SLC30A10. Chelation therapy with intravenous disodium calcium edetate was started in two 
siblings and led to a marked decrease in whole blood Mn. Oral Penicillamine was later added to the 
therapy which further improved blood Mn levels. This is a rare disorder and is one of the potentially 
treatable inherited metal storage disorders. It can be fatal if left untreated. Penicillamine may be an 
effective alternative to disodium calcium edetate. 
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Introduction:  
 
Manganese (Mn) is an essential trace metal that plays a critical role as a cofactor for a variety of 
enzymes involved in amino acid, lipid and carbohydrate metabolism, immune function, bone and 
connective tissue growth and blood clotting [1]. 
Despite its requirement in multiple physiological processes, elevated levels of Mn trigger toxicity, 
particularly within the central nervous system (CNS), causing cognitive, psychiatric and motor 
abnormalities [2].  
Mn intoxication can occur in different professionals [3], in individuals with chronic liver disease [4], in 
prolonged total parenteral nutrition administration [5] and in drug-addicts using Mn contaminated 
ephedrone peparations [6]. The first inborn error of Mn metabolism has recently been identified by 
Tuschl et al [7]. This autosomal recessive disorder, called Hypermanganesemia with Dystonia, 
Polycythemia and Cirrhosis (HMDPC), is caused by mutations in the SLC30A10 gene, encoding a Mn 
transporter, which  results in Mn accumulation, mainly in the basal ganglia, cerebellum  and  liver, and 
causes a syndrome of early-onset generalized dystonia, cirrhosis, polycythemia, and 
hypermanganesemia [7,8].  The characteristic MRI findings of this syndrome are hyperintense signals in 
the basal ganglia on T1 weighted and hypointense signals on T2 weighted images.  
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Case reports: 
We are reporting a case series of three siblings with childhood onset dystonia. Parents have a 
consanguineous marriage (first cousins) and have twelve children. The index case is 13 years old; the 
other affected siblings are 23 years and 8 years old. This family belongs to Sind, Pakistan. They consume 
tap water, the analysis of which yielded normal Mn levels. 
Patient 1  
The index case was a previously healthy 13 year old male with history of difficulty in walking which 
started at the age of 10 years and progressively worsened.  Slurred speech was present from two years 
of age.  In addition, difficulty in swallowing had developed recently. His birth history was uneventful. He 
achieved all milestones appropriate for his age. He went to school up until 10 years of age and had 
average performance in his studies. On general physical examination, his palms and conjunctivae were 
erythematous. Higher mental functions were intact and speech was dysarthric.   Motor examination 
showed marked dystonia of his limbs which was elicited during walking. There was no ataxia, tremors or 
cranial nerve involvement and systemic examination was unremarkable.  Initially, a differential diagnosis 
of Wilson's disease, Hallervorden-Spatz disease and hereditary dystonia was made.  Initial work up was 
remarkable for polycythemia while 24 hour urinary copper was normal (Table 1). MRI brain showed T1 
hyperintensity of globus pallidus, caudate nucleus, midbrain and tectum with concurrent hypointensity 
on T2 weighted images (Fig. 1). This suggested the possibility of iron or Mn deposition in the brain. 
Whole blood Mn was markedly raised at 14972.6 nmol/L (normal <320 nmol/L) suggesting a diagnosis of 
HMDPC. An ultrasound abdomen was done which showed no evidence of chronic liver disease or 
cirrhosis. SLC30A10 mutation analysis was performed, which was positive for a homozygous missense 
mutation in the 4th exon of the SLC30A10 gene (c.1006C>T; p. H336Y) (Fig 2). The child was started on 
disodium calcium edetate infusions at a dose of 1gm/m2 for 5 days every 6 weeks, and oral iron was 
also given. After 5 cycles of disodium calcium edetate infusions, blood Mn level had decreased to 1777.7 
nmol/ L.  Parents could not afford any further disodium calcium edetate, hence, a trial of Penicillamine 
was started and the Mn level was repeated after 6 months of therapy. There was a good response to 
Penicillamine noted as his Mn level had further declined to 1092 nmol/L. In addition he also showed 
clinical improvement in his overall motor activity. He was more stable in his walking and falling less and 
his dysphagia had improved.  
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Patient 2  
This previously healthy 8 year old boy started to have difficulty in speech for 6 months and difficulty in 
walking for 3 months. On examination he was active and alert. He had dysarthria and motor 
examination revealed significant dystonia of lower limbs during walking which resulted in tip toeing and 
subsequently difficulty in walking. There was no ataxia or tremors.  
Initial work up was also remarkable for polycythemia and high whole blood manganese levels (Table1). 
MRI brain showed the same findings as the index case.  This child had evidence of chronic liver disease 
on ultrasound only. Genetic evaluation confirmed the same homozygous mutation in the SLC30A10 gene 
(Fig 2). Treatment was started with disodium calcium edetate infusion and oral iron supplements. After 
4 cycles repeat blood Mn level had decreased (Table 1). Subsequently, Penicillamine was started and 
repeat Mn level was done after 6 months. There was a good response to Penicillamine and his Mn level 
decreased significantly, along with clinical improvement in dystonia. 
 
Patient 3  
This 23 year old male was well up to the age of 6 years when he started having difficulty in walking and 
speaking which was followed by frequent falls.  He eventually became wheel chair bound within a few 
months. On examination he had dysarthria but his cognitive functions were good. He had increased 
tone, dystonia of limbs and contractures of lower limbs with no cranial nerve involvement. He had no 
involuntary movements.  His laboratory work up was also remarkable for polycythemia and high whole 
blood Mn level (Table 1). The MRI brain showed similar changes in the basal ganglia as the index case. 
Genetic evaluation confirmed the homozygous mutation in the SLC30A10 gene. He has also been 
recently started on oral penicillamine and iron supplements.  
The father and one other unaffected sibling were shown to be heterozygous for the p. H336Y mutation. 
Genetic testing for the rest of the family could not be done as DNA samples were not available (Fig 2). 
The mutation identified has been reported in heterozygous state in one South Asian individual with an 
allele frequency of 1:8252 on the ExAC database (http://exac.broadinstitute.org). 
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Discussion: 
SLC30A10 is a crucial Mn transporter in man. In individuals with homozygous SLC30A10 mutations, 
hepatic Mn excretion is severely defective, leading to Mn accumulation in the liver, the bloodstream, 
the brain and other peripheral tissues [9]. Mn induces erythropoietin gene expression leading to 
polycythemia. 
In all three patients symptoms started before 10 years of age and common presentation was difficulty in 
walking, dysarthria and dystonia. The index case presented at 13 years of age and after his diagnosis was 
established the parents brought the other two siblings for evaluation. The younger sibling was 6 years at 
presentation and he had only very mild symptoms while the older sibling was already wheel chair 
bound.  All had polycythemia on presentation while hepatic dysfunction was only seen in patient 2 who 
had evidence of chronic liver disease. Quadri et al also report that hepatic dysfunction may vary 
between members of the same family [7,8]. 
Some intrafamilial clinical heterogeneity was noted amongst our children and this has been observed by 
Delnooz et al. The characteristic MRI findings of this syndrome are hyperintense signals in the basal 
ganglia on T1 weighted images and hypointense signals on T2 weighted images. The reverse is seen in 
copper deposition in Wilson’s disease which shows hypointense signals on T1 weighted images and 
hyperintense signals on T2 weighted images in the basal ganglia. The diagnosis of this rare syndrome is 
confirmed by identification of bi-allelic mutations in the SLC30A10 gene.  SLC30A10 has recently been 
identified as the disease causing gene by Tuschl et al and four Pakistani siblings were amongst the initial 
group reported [10].  
The mainstay of treatment is chelation therapy. Chelation therapy with disodium calcium edetate  
(CaNa2-EDTA 1g/m2 daily) [11] enhances  urinary Mn excretion and  significantly improves neurological 
symptoms [7].  
Other chelating agents have been used including oral dimercaptosuccinic acid (DMSA) and Para-
aminosalicylic acid [12]. In our patients only two were started on disodium calcium edetate. 
The role of Penicillamine has not been evaluated extensively in the treatment of this disorder.  We used 
Penicillamine which showed an excellent response in declining blood Mn levels and a relatively good 
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clinical response in both patients. There is a possibility that Penicillamine may be used in the treatment 
of hypermanganesemia, however long term efficacy of this drug in this disorder remains to be 
evaluated. 
 
 
 
Conclusion: 
We wish to highlight this rare disorder which, together with Wilson’s disease, is the only potentially 
treatable inherited metal storage disorder to date. The role of Penicillamine as an effective Mn chelator 
needs to be further evaluated.  
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Table1: 
Clinical and laboratory findings of patients with Hypermanganesemia, Polycythemia, Dystonia and 
Cirrhosis.               
                                                              Case 1                                     Case 2                                   Case 3 
Gender                                                 Male                                           Male                                   Male 
Age of patient                                    13 yrs                                          8yrs                                    23 yrs 
Dystonia                                               Present                                      Present                              Present 
Dysarthria                                            Present                                      Present                              Present 
Hepatomegaly                                       No                                            No                                      No 
Hemoglobin *(13-16g/dl)                  20.7g/dl                                   18.3gm/dl                         16.4gm/dl   
Hematocrit *(42-16%)                        61.7%                                        53.5%                                  47.6%    
SGPT * (<45IU/L)                               43IU/L                                      44 IU/L                               38IU/L   
Ferritin levels                                     13.2ng/ml                                 --                                          -- 
*(7-140ng/ml)                                                                                                                                                  
24hrs urinary Copper                        18ug/day                                   --                                          --  
*(<60ug/day)                                                                                                                                                             
Erythropoietin                                       18.55                                       --                                           --    
*(3.3-16.6 U/m)                                                                                                                                                        
Blood Mn level                                14972.6 nmol/L                    1511 nmol/L                      539 nmol/L   
*(<320nmol/L)     
Blood Mn levels after 6 months     1777.7nmol/L                  1481.4 nmol/L                            --                                                                                                                                                                         
Ultrasound liver                                Normal                           Chronic liver disease                    Normal     
MRI brain suggestive of                    Yes                                            Yes                                           Yes   
Mn deposition                                                 
SLC30A10 mutations                      Positive                                    Positive                                     Positive    
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-- not done,  
*normal range 
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Figure 1 
MRI brain axial view of Index case 
 
 
 
 
 
 
 
 
 
 
 
 
 
1(a). Axial view of Index case, arrows indicating bilateral hyperintense signals on TW1 image in 
basal ganglia along with few cystic changes in this region.  
1(b). Bilateral Hypointense signals on TW2 image in basal ganglia. 
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Figure 2 
Pedigree and sequencing analysis of SLC30A10 
2(b)  
      
 
2(a)           c.1006C >T  
                  p.H336Y 
I:1 (father) 
II:3 (affected sibling) 
 
II:2 (affected sibling) 
 
I1:1 (affected sibling) 
11:4 (unaffected sibling) 
2(a). Pedigree of the described family: Affected individuals are indicated by black shading.  
2(b). Sequence chromatograms showing a homozygous missense change (c.1006C>T) in three 
affected siblings (II:1, II:2 and II:3). Sequence analysis of DNA from the father (I:1) and an unaffected 
sibling (II:4) confirms that they are heterozygous carriers for the identified mutation. DNA from the 
mother and the remaining siblings was unavailable. Mutated bases are boxed in black.  
 
